Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

Exclusion Criteria

• •Patients who are receiving any other investigational agents.
• •PSA greater than or equal to 20 ng/dL if no prior 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) scan obtained (If PSA \> 20 and 18F-DCFPyL obtained within 3 months prior to enrollment shows no evidence of metastatic disease, subjects may be included in the study)
• •Biochemical recurrence within one year of completion of radiotherapy
• •Need for chronic anticoagulation therapy (chronic low dose aspirin is not an exclusion)
• •Pre-existing and ongoing radiation-related grade 3 bowel or bladder toxicity
• •Inflammatory bowel disease
• •Active Lupus or Active scleroderma
• •Patients with distant metastatic disease (prostate adjacent adenopathy is not an exclusion)
• •Prior prostatectomy
• •Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
• •Subjects with severe claustrophobia that is unresponsive to oral anxiolytics
• •Other medical conditions deemed by the Principal Investigator (or associates) to make the subject unsafe or ineligible for protocol procedures
• •Subjects weighing \> 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry
• •Serum creatinine \> 2 times the upper limit of normal
• •Total bilirubin \> 2 times the upper limit of normal OR in patients with Gilbert's syndrome, a total bilirubin \> 3.0.
• •Liver transaminases (alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than 3 times the upper limit of normal
• •Patients with positive Human Immunodeficiency Virus (HIV) status and currently requiring treatment with agents known to sensitize to irradiation, such as protease inhibitors.